查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
干粉吸入器全球市场-2022-2029
市场调查报告书
商品编码
1146429

干粉吸入器全球市场-2022-2029

Global Dry Powder Inhalers Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

预计 2021 年干粉吸入器市场规模将达到 9.37 亿美元，预计在预测期间（2022-2029 年）将以 5.1% 的复合年增长率增长。

干粉吸入器 (DPI) 以干粉形式将药物输送到呼吸系统疾病患者的肺部。由于对在 P-MDI 中用作推进剂的氯氟烃 (CFC) 的环境问题日益关注，DPI 优于加压计量吸入器。

市场动态

由于哮喘和慢性阻塞性肺病的发病率和患病率上升、技术进步和人口老龄化，对干粉吸入器的需求不断增加，推动了全球干粉吸入器市场。

新药技术进步推动市场增长

预计技术进步将在预测期内推动市场增长。传统疗法的局限性，例如起效慢和疗效低，预计将推动新型靶向药物的开发，从而推动市场。例如，赛诺菲在 2021 年 2 月与 Regeneron 合作宣布，itepekimab 与患有中度至重度慢性阻塞性肺病 (COPD) 的前吸烟者的急性中度至重度 COPD 恶化有关。已开始评估有效性和安全性。该试验计划于 2024 年 7 月结束。市场参与者正在采取各种策略，例如产品发布、开发、合作伙伴关係、收购和扩张，以增加他们的市场份额。例如，2020 年 7 月，龙沙在其位于俄勒冈州本德的现有工厂启动了干粉吸入器 (DPI) 药物开发卓越中心，该公司将利用其粒子工程专业知识优化客户配方。我们计划帮助创建和评估。

根据世界卫生组织 (WHO) 2021 年情况说明书，COPD 是全球第三大死因，在 2019 年造成 323 万人死亡。超过 80% 的死亡发生在低收入和中等收入国家 (LMIC)。此外，全球老龄化人口的增加也在推动市场增长。

哮喘治疗的高成本预计将阻碍市场增长

哮喘吸入器的高成本可能会限制该行业的扩张。越来越多的患者接受呼吸手术并患有哮喘和慢性阻塞性肺病等慢性或呼吸系统疾病，因此需要创新的吸入器。然而，这些疾病设备的高成本可能会减少低收入国家对吸入器的采用。例如，根据 TalktoMira, Inc. 的数据，没有保险的品牌哮喘吸入器的平均价格为 292.91 美元。

这些小工具和所需配件的高价可能会限制市场扩张。在拥有大量低收入人口的不发达国家，哮喘治疗的高成本可能会限制市场增长。因此，中低收入国家可能难以引进如此昂贵的设备。因此，这些先进设备的高价格可能会在估计数年内抑制吸入器市场的增长。

COVID-19 影响分析

COVID-19 影响了全球药品供应链，并影响了哮喘和 COPD 药品市场。 Jose Luis Izquierdo 等人于 2021 年 3 月在《欧洲呼吸杂誌》上发表的一项研究发现，使用 COVID-19 的哮喘患者的鼻炎和湿疹等过敏相关因素较少。在需要住院的 COVID-19 患者中也观察到这些合併症的高频率。

此外，因 COVID-19 需要住院的患者使用的吸入性皮质类固醇 (ICS) 少于未住院患者（48.3% 对 61.5%）。接受生物製剂治疗的患者在耳鼻喉科领域的严重程度和并发症增多，但这些患者因 COVID-19 住院的比例相对较低（0.23%）。因此，患有哮喘和 COVID-19 的患者年龄较大，并且与合併症相关的因素的风险增加。吸入性皮质类固醇 (ICS) 和生物製剂通常是安全的，并且可能与针对严重 COVID-19 感染的保护功效有关。患有慢性阻塞性肺病 (COPD) 的患者如果发展为 COVID-19，则其患重症肺炎的风险会增加且预后不良。这可能与潜在的肺储备低或小气道中 ACE-2 受体的表达增加有关。

行业分析

全球干粉吸入器市场基于波特五力、监管分析、供应链分析和定价分析、报销政策、技术进步、PEST 分析等各种行业因素。市场详细信息提供了全面的分析。

细分分析

胶囊装置细分市场有望在全球干粉吸入器市场占据最大份额

基于胶囊的设备细分市场受到以下因素的推动：在该细分市场提供多样化产品的製造商数量增加、医疗保健专业人员和患者对这些设备的采用和偏好增加，以及普及率和哮喘发病率预计将主导全球干粉吸入器市场。例如，2019 年 5 月，龙沙（Lonza）推出了 Capsugel Zephyr，一种经过优化的干粉吸入胶囊组合，可在胶囊/装置和胶囊/製剂之间提供卓越的性能和兼容性。

哮喘患病率和发病率的显着增加导致患者数量增加，从而导致对这些设备的需求增加。根据世界卫生组织 (WHO) 2021 年情况说明书，哮喘是一种主要的非传染性疾病 (NCD)，影响儿童和成人。在全球范围内，2019 年估计有 2.62 亿人被感染，461,000 人死亡。对哮喘药物研究的巨额投资以及併购等战略联盟是市场主要参与者采取的商业战略。例如，2019 年 10 月，美国食品药品监督管理局 (FDA) 批准了阿斯利康的哮喘药物 Fasenra 用于自我给药（一种预填充的一次性自动注射器）。

按地区分析

北美在全球干粉吸入器市场中占有最大份额

由于慢性阻塞性肺病和哮喘等疾病的发病率上升、人口老龄化、研发活动增加、主要市场参与者的存在等，北美在干粉吸入器市场占据主导地位。预计在预测期内将显示出类似的趋势.

在美国，成年女性的哮喘发病率高于成年男性。根据 2020 年疾病控制和预防中心的数据，美国约有 2500 万美国人患有哮喘。这大约是 13 个美国人中的 1 个，其中 8% 是成年人，7% 是儿童。大约 2000 万美国 18 岁以上的成年人患有哮喘。同样，在加拿大，哮喘是一个主要的公共卫生问题。哮喘是一种终生呼吸道疾病，影响加拿大人的工作效率、生活质量、心理健康和心理健康。根据加拿大 2019 年哮喘调查年度报告，2019 年加拿大有超过 380 万人患有哮喘。由于受哮喘影响的人数众多，对治疗目标疾病的药物的需求正在增加，从而推动了该地区的增长。

竞争格局

由于该行业的主要市场参与者，干粉吸入器市场竞争激烈。为全球市场增长做出贡献的一些主要干粉吸入器製造商包括 AstraZeneca PLC、Boehringer Ingelheim GmbH、Vectura Group plc、Otsuka Pharmaceutical Co. Ltd、Norton Healthcare、Respira Therapeutics, Inc、Chiesi、Cipla 等。领先的公司正在采用多种增长战略，例如产品发布、收购和合作伙伴关係，这有助于全球市场的增长。例如，2021年3月，Glenmark Pharmaceuticals Ltd.在英国推出了生物等效版本的塞托溴铵干粉吸入器（DPI），商品名为-Tiogiva，用于治疗慢性阻塞性肺病（COPD）。

值得关注的重点公司

Vectura Group PLC

概述 Vectura Group PLC 开髮用于治疗呼吸系统疾病的吸入疗法。我们的主导产品用于治疗哮喘和慢性阻塞性肺病。我们还开髮用于肺部疾病和非呼吸系统的产品。

Vectura 的主要产品有 10 种吸入式和 11 种非吸入式产品，并由全球拥有版税收入来源的合作伙伴销售。我有一个产品组合。

产品组合 Gyrohaler：一种多桶干粉吸入器，旨在将局部作用的药物输送到肺部。

关键发展：2021 年，Vectura 将扩大其在英国奇彭纳姆工厂的干粉吸入器开发和製造能力。

本报告提供对全球干粉吸入器市场约 45 多个市场数据表、40 多个图表和 180 页的访问权限。

内容

第 1 章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

  • 按产品类型划分的市场细分
  • 按适应症类型划分的市场细分
  • 按分销渠道划分的市场细分
  • 按地区划分的市场细分

第 4 章市场动态

  • 市场影响因素
  • 促进因素
    • 呼吸设备的普及率提高
    • 空气污染水平不断上升，尤其是在发展中国家
  • 抑制因素
    • 剂量不均匀，设备成本高
  • 影响分析

第 5 章行业分析

  • 波特五力分析
  • 供应链分析
  • 法律法规分析
  • 定价分析
  • 技术进步
  • 保险报销分析
  • 未满足的需求

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按产品类型

  • 胶囊装置
  • 泡罩式设备
  • 储液器/筒式装置
  • 其他

第 8 章疗效

  • 支气管炎
  • 慢性阻塞性肺病 (COPD)
  • 哮喘
  • 其他

第 9 章按销售渠道

  • 医院药房
  • 在线药店
  • 零售药房
  • 药店

第 10 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章竞争格局

  • 竞争场景
  • 关键战略分析
  • 技术组合对比分析
  • 市场情况/份额分析
  • 併购分析

第 12 章公司简介

  • Vectura Group plc
    • 公司简介
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • GlaxoSmithKline plc
  • AstraZeneca
  • Boehringer Ingelheim GmbH
  • Otsuka Pharmaceutical Co. Ltd
  • Norton Healthcare
  • Respira Therapeutics, Inc
  • Boehringer Ingelheim
  • Chiesi
  • Cipla

第 13 章全球干粉吸入器市场-DataM

简介目录
Product Code: DMMD1827

Market Overview

Dry Powder Inhalers Market size was valued US$937 million in 2021 and is growing at a CAGR of 5.1% during the forecast period (2022-2029).

Dry powder inhalers (DPI) deliver drugs in the form of dry powder to the lungs of patients suffering from respiratory disorders. These are preferred over pressurized metered dose inhalers due to rising environmental concerns regarding chloro-flouro carbon (CFC) used as a propellant in P-MDIs.

Market Dynamics

The global dry powder inhalers market is due to an increasing demand of dry powder inhalers owing to the rise in incidence and prevalence of asthma and COPD, technological advancements, and a growing geriatric population.

Technological advancements in novel drugs drives the growth of the market

Technological advancements are anticipated to drive the growth of the market in the forecast period. Limitations of traditional treatments, such as the late onset of action and low efficacy, are projected to encourage the development of novel targeted drugs, thereby driving the market. For instance, in February 2021, Sanofi, in collaboration with Regeneron Pharmaceuticals, initiated a Phase III clinical trial to assess the efficacy and safety of itepekimab on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe chronic obstructive pulmonary disease (COPD). The trial is expected to be completed in July 2024. The market players are adopting various strategies such as product launches, developments, collaborations, acquisitions, and expansions to increase their market shares. For instance, In July 2020, Lonza launched a Center of Excellence for Dry Powder Inhaler (DPI) drug product development at its exsiting facility in Bend, OR, in which the company will use its expertise in particle engineering to help customers to create and evaluate formulations.

According to the World Health Organization (WHO) 2021 factsheet, COPD is the third-leading cause of death worldwide, causing 3.23 million deaths in 2019. Over 80% of these deaths occurred in low- and middle-income countries (LMIC). Moreover, the increasing geriatric population globally is boosting the market growth.

The high cost of asthma treatment is expected to hamper the market growth

The expensive cost of asthma inhalers could limit industry expansion. A growing proportion of patients undergoing respiratory operations need innovative inhalers because they have chronic and respiratory disorders like asthma and COPD. However, the adoption rate of inhalers may decline throughout low-income countries as a result of the high cost of these devices for these disorders. For instance, according to the TalktoMira, Inc, the average price of one brand-name asthma inhaler is $292.91 without insurance.

The expensive price of these gadgets and necessary accessories could limit market expansion. Market growth in underdeveloped nations with relatively low-income levels may be constrained because to the high costs involved with asthma procedures. As a result, it might be challenging for middle-income and low-income countries to adopt such expensive devices. Therefore, the high price of these advanced devices could restrain the expansion of the inhalers market over the estimated year.

COVID-19 Impact Analysis

COVID-19 impacted the global supply chain of pharmaceuticals, affecting the Asthma and COPD drug market. According to a research study by Jose Luis Izquierdo et al., published in the European Respiratory Journal, March 2021, allergy-related factors such as rhinitis and eczema were less common in asthmatic patients with COVID-19. There was a high prevalence of these comorbidities observed in patients with COVID-19 who required hospital admission.

Furthermore, the use of inhaled corticosteroids (ICS) was lower in patients who required hospitalization due to COVID-19 compared to non-hospitalized patients (48.3% versus 61.5%). Although patients treated with biologics showed increased severity and more comorbidities at the ear, nose, and throat levels, COVID-19-related hospitalizations in these patients were relatively low (0.23%). Thus, patients with asthma and COVID-19 were older and at increased risk due to comorbidity-related factors. Inhaled corticosteroids (ICS) and biologics are generally safe and may be associated with a protective effect against severe COVID-19 infection. Chronic obstructive pulmonary disease (COPD) patients have an increased risk of severe pneumonia and poor outcomes when they develop COVID-19. This may be related to poor underlying lung reserves or increased expression of ACE-2 receptors in small airways.

Industry Analysis

The global dry powder inhalers market provides in-depth analysis of the market based on various industry factors such as porter's five forces, regulatory analysis, supply chain analysis and pricing analysis, reimbursement policies, technological advancements, PEST analysis.

Segment Analysis

The capsule based devices segment is expected to hold the largest market share in global dry powder inhalers market

The capsule based devices segment is expected to dominate the global dry powder inhalers market, owing to increase in number of manufacturers offering diverse products in the segment and rise in adoption and preference of health care providers and patients for these devices and also increase in prevalence and incidence of asthma. For instance, In May 2019, Capsugel Zephyr is launched by Lonza, a dry-powder inhalation capsule portfolio that is optimized to provide superior performance and compatibility between the capsule/device and capsule/formulation.

The substantial increase in prevalence and incidence of asthma has led to an increase in the patient population, which has, in turn, increased the demand for these devices. According to the World Health Organization (WHO) 2021 factsheet, asthma is a major non-communicable disease (NCD), affecting both children and adults. Globally, it affected an estimated 262 million people in 2019 and caused 461,000 deaths. Enormous investments in the study of asthma drugs accompanied by strategic collaborations such as mergers and acquisitions are the business strategies followed by the major companies in the market. For instance, in October 2019, the US Food and Drug Administration (FDA) approved the self-administration of AstraZeneca's asthma drug Fasenra, a pre-filled, single-use auto-injector.

Geographical Analysis

North America region holds the largest market share in the global dry powder inhalers market

North America dominates the market for dry powder inhalers and is expected to show a similar trend over the forecast period, owing to the rising incidence of diseases such as COPD and asthma, the aging population, increasing research and development activities, and the presence of key market players.

In the United States, asthma is more common in adult women than adult men. According to the Centers for Disease Control and Prevention 2020 report, in the United States, approximately 25 million Americans have asthma. This equals to about 1 in 13 Americans, including 8% of adults and 7% of children. About 20 million US adults aged 18 years and over have asthma. Similarly, asthma is a major public health concern in Canada. As a lifelong respiratory illness, asthma affects the work productivity, quality of life, mental health, and psychological well-being of the Canadian population. In Canada, over 3.8 million individuals had asthma in 2019, as per Canada's 2019 annual asthma survey report. The high number of patients affected by asthma increases the demand for drugs for the treatment of the target disease, thereby boosting the growth of this region.

Competitive Landscape

The dry powder inhalers market is highly competitive, owing to big market players in the industry. The key dry powder inhalers players which are contributing to the growth of the global market include AstraZeneca PLC, Boehringer Ingelheim GmbH, Vectura Group plc, Otsuka Pharmaceutical Co. Ltd, Norton Healthcare, Respira Therapeutics, Inc, Chiesi, Cipla and among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, in March 2021, Glenmark Pharmaceuticals Ltd, launched a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) under the brand name - Tiogiva, in UK for the treatment of chronic obstructive pulmonary disease (COPD).

Key Companies to Watch

Vectura Group PLC:

Overview: Vectura Group PLC develops inhaled therapies for the treatment of respiratory diseases. The Company's main products are used to treat asthma and chronic obstructive pulmonary disease. Vectura also develops products for lung pathologies and non-respiratory.

Vectura has ten key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development.

Product Portfolio: Gyrohaler: is a multi-unit dose dry powder inhaler designed to deliver locally acting drugs to the lungs.

Key Developments: In 2021, Vectura expands dry powder inhaler development and manufacturing capabilities at its facility in chippenham, U.K.

The global dry powder inhalers market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Product Type
  • 3.2. Market Snippet by Indication Type
  • 3.3. Market Snippet by Distribution Channel
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
  • 4.2. Drivers
    • 4.2.1. Increasing Prevalence of Respiratory Devices
    • 4.2.2. Increasing Air Pollution Levels Especially in Developing Countries
  • 4.3. Restraints
    • 4.3.1. Inaccuracy In Dose Uniformity and High Cost of Devices
  • 4.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porters Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pricing Analysis
  • 5.5. Technological Advancements
  • 5.6. Reimbursement Analysis
  • 5.7. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Product Type
  • 7.3. Market Attractiveness Index, by Product Type
  • 7.4. Capsule Based Device *
    • 7.4.1. Introduction
    • 7.4.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.5. Blister Based Devices
  • 7.6. Reservoir/Cartridge Based Devices
  • 7.7. Others

8. By Indication Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Indication Type
    • 8.1.2. Market Attractiveness Index, by Indication Type
  • 8.2. Bronchitis*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Chronic Obstructive Pulmonary Diseases (Copd)
  • 8.4. Asthma
  • 8.5. Others

9. By Distribution Channel

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Distribution Channel
  • 9.3. Market Attractiveness Index, by Distribution Channel
  • 9.4. Hospital Pharmacies *
    • 9.4.1. Introduction
  • 9.5. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.6. Online Pharmacies
  • 9.7. Retail Pharmacies
  • 9.8. Drug Stores

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Product Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Indication Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Countries
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Product Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Indication Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Countries
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Product Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Indication Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Countries
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Product Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Indication Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Countries
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Product Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Distribution Channel
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Key Strategy Analysis
  • 11.3. Comparative Technology Portfolio Analysis
  • 11.4. Market Positioning/Share Analysis
  • 11.5. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Vectura Group plc *
    • 12.1.1. Company overview
    • 12.1.2. Product portfolio and description
    • 12.1.3. Key highlights
    • 12.1.4. Financial overview
  • 12.2. GlaxoSmithKline plc
  • 12.3. AstraZeneca
  • 12.4. Boehringer Ingelheim GmbH
  • 12.5. Otsuka Pharmaceutical Co. Ltd
  • 12.6. Norton Healthcare
  • 12.7. Respira Therapeutics, Inc
  • 12.8. Boehringer Ingelheim
  • 12.9. Chiesi
  • 12.10. Cipla

LIST NOT EXHAUSTIVE

13. Global Dry Powder Inhalers Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us